Nearly 40% of healthcare collections now come from uninsured patients, up 54% in the past three years, a new report from Cedar found. The health tech company surveyed 4,150 patients across the U.S.

A drug that helped turn Novo Nordisk into Europe's most valuable company is about to lose its monopoly grip across much of the globe. Patent protections on semaglutide—sold as Ozempic for diabetes and ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Dany Lepage discusses the architectural ...

After delivering solid sales growth in a difficult 2025, Germany’s Merck KGaA may have a tougher go of things this year, which the company is crediting in part to a predicted onslaught of U.S.

Aspen Pharmacare (APNHF) expects Canadian regulators to approve its generic version of Novo Nordisk’s (NVO) (NONOF) blockbuster diabetes therapy Ozempic by September, the CEO of the South African ...

Africa’s largest drugmaker expects to get approval in Canada for its generic GLP-1 obesity treatment by September, potentially giving it an early start in a key market after Novo Nordisk A/S’s Ozempic ...

The following is a news release from the Idaho Attorney General's Office: BOISE, Idaho — On February 2, 2026, Attorney General Labrador joined a coalition of 48 states and territories announcing ...

In 2025 the Department of Education announced it would resume involuntary collections, but has put off implementation. Wage garnishment and Treasury offset are measures the government could enact to ...

Novartis NOVN0.89%increase; green up pointing triangle said it expected a key profitability metric to decline this year in large part due to increased competition in the U.S. from generic drug ...

In January 2026, regulatory exclusivity for semaglutide in Canada expired, creating a pathway for regulated generic competition and drawing global attention to Canada as an early major market for ...